Changes in Hong Kong stocks | CSPC Group (01093) rose more than 4% SYS6010 was recently included in the list of breakthrough treatment varieties by the State Drug Administration

The Zhitong Finance App learned that CSPC Group (01093) rose by more than 4%. As of press release, it had risen 4.09% to HK$9.545, with a turnover of HK$759 million.

According to the news, Shiyao Group announced that SYS6010 (this product) developed by the Group has recently been included in the list of breakthrough treatment varieties by the China National Drug Administration (CNDA). The proposed indication is recurrent or metastatic head and neck squamous cancer (R/MHNSCC) that has previously been treated with failed immunization and platinum-containing chemotherapy. The product significantly improved the objective remission rate and long-lasting relief for patients with recurrent or metastatic head and neck squamous cell carcinoma who had previously failed immunization and platinum-containing chemotherapy. Currently, critical phase III clinical trials of this single drug for recurrent or metastatic head and neck squamous cell carcinoma that have failed immunization and platinum-containing chemotherapy are ongoing.

Previously, the product has obtained 2 breakthrough treatment certifications granted by the State Drug Administration (excluding this one). The proposed indications are: single drug for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) that failed to be treated with EGFR-TKI and platinum-containing chemotherapy; unresectable locally advanced or metastatic esophageal squamous cell carcinoma that has failed after receiving platinum-containing chemotherapy and immune checkpoint inhibitors (ICI) on the frontline.